High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Melinda B., Fesler, Mark J., Armbrecht, Eric S., Fosko, Scott W., Hsueh, Eddy, Richart, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666432/
https://www.ncbi.nlm.nih.gov/pubmed/23762555
http://dx.doi.org/10.1155/2013/726925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666432/
https://www.ncbi.nlm.nih.gov/pubmed/23762555
http://dx.doi.org/10.1155/2013/726925

Ejemplares similares